- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02820116
The Role of Icotinib in the Perioperative Treatment of IIIA - IIIB NSCLC Patients With EGFR Mutation
An Open-label, Multicenter,Single-arm, Phase II Clinical Study of Icotinib for IIIA - IIIB NSCLC Patients With Epidermal Growth Factor Receptor Mutation
This is an open-label, multicenter, single-arm, phase II interventional clinical trial evaluating efficacy and safety of Icotinib as neoadjuvant treatment in patients with IIIA- IIIB NSCLC with activating EGFR mutation in exon 19 or 21. Sixty-seven resectable stage IIIA- IIIB NSCLC patients with EGFR activating (19/21) mutations will be eligible to be enrolled. EGFR mutation will be prospectively tested in all the participants' biopsy samples and confirmed in surgical resected samples.
Neoadjuvant treatment phase:
Eligible patients will receive 125mg of Icotinib three times per day. Treatment will be scheduled to continue until the disease progression or unbearable toxicities appear.
Surgery treatment phase:
Tumor response will be evaluated with CT scan after 8 weeks of induction treatment. The patients with responsive disease considered to be technique resectable will undergo resection.
Post-surgery phase:
It is the discretion of the investigator whether the patient is a candidate for post-operative treatment which is considered to be in the best interest of the patients. It is recommended that patients with positive margins or residual tumor after surgery should receive radiation therapy. Patients after surgery will receive long-term follow-up -- chest CT scan,abdominal abdominal ultrasound every 3 months, brain MRI every 6 months, bone scan (ECT) every 12 months -- for up to 5 years.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Yuqing Huang, Doctor
- Phone Number: +8601082693152
- Email: huangyuqing555@gmail.com
Study Contact Backup
- Name: Jun liu, doctor
- Phone Number: +8601082693152
- Email: liujundaifu@yahoo.cn
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100080
- Recruiting
- Beijing Haidian Hospital
-
Contact:
- Yuqing Huang, Doctor
- Phone Number: +8601082693152
- Email: huangyuqing555@gmail.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Provision of informed consent
- Pathologically confirmed non-small cell lung cancer with EGFR exon 19 deletion or exon 21 L858 mutation.
- Clinically or pathologically confirmed stage IIIA- IIIB
- Tolerable to complete resection of lung cancer
- Able to comply with the required protocol and follow-up procedures, and able to receive oral medications
- ECOG performance status 0-1.
- Life expectancy ≥12 weeks.
- Measurable disease must be characterized according to RECIST 1.1 criteria. Measurable lesions are defined as those that can be accurately measured in at least one dimension as ≥ 10mm by spiral CT scan.
- Adequate hematological function: Absolute neutrophil count (ANC) ≥2.0 x 109/L, and Platelet count ≥100 x 109/L, and Hemoglobin ≥10 g/dL (may be transfused to maintain or exceed this level).
- Adequate liver function: Total bilirubin ≤ 1.5 x upper limit of normal (ULN); Aspartate amino transferase (AST) and alanine amino transferase (ALT) ≤ 2.5 x upper limit of normal (ULN).
- Adequate renal function: Serum creatinine ≤ 1.25 x upper limit of normal (ULN), and creatinine clearance≥ 60 ml/min.
- Measurable disease according to the preset criteria .
Exclusion Criteria:
- Patients with prior exposure to chemotherapy, irradiation or systemic anti-cancer therapy (e.g. monoclonal antibody therapy) for lung cancer.
- Known severe hypersensitivity to Icotinib or any of the excipients of this product
- Previous or current malignancies of other histologies within the last 5 years with the exception of the following: other malignancies cured by surgery alone and having a continuous disease-free survival of 5 years; cured basal cell carcinoma of the skin and cured in situ carcinoma of the uterine cervix.
- Any unstable systemic disease (including active infection, uncontrolled hypertension, unstable angina, congestive heart failure, myocardial infarction within six months, serious cardiac arrhythmia requiring medication, hepatic, renal, or metabolic disease).
- Interstitial lung disease(ILD) or pulmonary fibrosis; impaired pulmonary function.
- Eye inflammation or eye infection not fully treated or predisposing factor of this.
- Uncontrolled central nervous system (CNS) metastasis.
- Any serious concomitant systemic disorder that, in the opinion of the investigator, would compromise the patient's ability to complete the study
- Evidence of any other disease, neurological or metabolic dysfunction, physical examination or laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or puts the subject at high risk for treatment-related complications.
- Pregnancy or breast feeding.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Icotinib
Patients receive Icotinib PO TID for 8 weeks and then undergo thoracotomy.
|
In the neoadjuvant treatment phase, eligible patients will receive 125mg of Icotinib three times per day for 8 weeks (56 days).
In the post-surgery phase, Icotinib 125mg/three tims/day taken orally for 2 years or till disease progression or unacceptable toxicity.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Complete resection rate
Time Frame: Complete resection rate is depended on the pathology diagnosis after surgery, an expected average of 8 weeks from enrollment.
|
Complete resection rate is depended on the pathology diagnosis after surgery, an expected average of 8 weeks from enrollment.
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Objective response rate(ORR, i.e., complete response [CR] + partial response [PR])
Time Frame: Up to 5 years
|
Up to 5 years
|
Disease control rate (CR + PR+ stable disease)
Time Frame: Up to 5 years
|
Up to 5 years
|
Clinical down-staging
Time Frame: 8 weeks
|
8 weeks
|
Progression free survival (PFS)
Time Frame: Participants after surgery will receive long-term follow-up for up to 5 years
|
Participants after surgery will receive long-term follow-up for up to 5 years
|
Overall survival (OS)
Time Frame: Participants after surgery will receive long-term follow-up for up to 5 years
|
Participants after surgery will receive long-term follow-up for up to 5 years
|
Number of Adverse Event
Time Frame: Within 28 days of last study dose
|
Within 28 days of last study dose
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Jun liu, doctor, Peking University People Hospital
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- RIPOT1606
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non-small Cell Lung Cancer(NSCLC)
-
H. Lee Moffitt Cancer Center and Research InstituteNestle Health ScienceWithdrawnNSCLC | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | NSCLC Stage IIIB | Non-small Cell Lung Cancer Stage IIIB | NSCLC, Stage IIIA | Non-small Cell Lung Cancer Stage ⅢAUnited States
-
ElephasBeaufort CRORecruitingNSCLC | Non Small Cell Lung Cancer | Metastatic Non Small Cell Lung Cancer | Metastatic NSCLC - Non-Small Cell Lung CancerUnited States
-
Mythic TherapeuticsRecruitingNon-Small Cell Lung Cancer | NSCLC | Advanced Non-Small Cell Lung Cancer | NSCLC Stage IV | NSCLC Stage IIIB | Advanced Non-Small Cell Squamous Lung Cancer | Advanced Non-Small Cell Non-Squamous Lung CancerUnited States, Australia, Korea, Republic of, United Kingdom
-
Jun Zhang, MD, PhDGenentech, Inc.; ExelixisNot yet recruitingLung Cancer | NSCLC Stage IV | Advanced NSCLC | Metastatic NSCLC - Non-Small Cell Lung CancerUnited States
-
Memorial Sloan Kettering Cancer CenterRecruitingNSCLC | Non Small Cell Lung Cancer | Non Small Cell Lung Cancer Metastatic | NSCLC Stage IV | Non-small Cell CarcinomaUnited States
-
University of Alabama at BirminghamSanofiCompletedNon-small Cell Lung Cancer (NSCLC) | Metastatic NSCLC | Stage IV NSCLCUnited States
-
Oslo University HospitalAstraZenecaActive, not recruitingCancer | NSCLC | Non Small Cell Lung Cancer | NSCLC, Stage III | Non Small Cell Lung Cancer Stage IIINorway, Finland, Lithuania, Estonia
-
Heather WakeleeNovartis; Genentech, Inc.TerminatedNon-small Cell Lung Cancer (NSCLC), Recurrent | Non-small Cell Lung Cancer (NSCLC), Stage IVUnited States
-
Radiotherapy Oncology Centre "Santa Maria" HospitalPaola Anselmo,MD; Michelina Casale,PhD; Fabio Trippa,MDRecruitingNSCLC | Non Small Cell Lung Cancer | EGF-R Positive Non-Small Cell Lung Cancer | Non Small Cell Lung Cancer Metastatic | NSCLC Stage IV | Oligometastatic Disease | Non-Small Cell Squamous Lung Cancer | Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor | Non-Small Cell Adenocarcinoma and other conditionsItaly
-
AmgenParexelWithdrawnMetastatic Non-small Cell Lung Cancer (NSCLC) | Non-squamous NSCLC
Clinical Trials on Icotinib
-
Anhui Medical UniversityUnknown
-
Betta Pharmaceuticals Co., Ltd.RecruitingNon-Small Cell Lung Cancer | Adjuvant Therapy | EGFR Sensitive MutationChina
-
Li PengBetta Pharmaceuticals Co., Ltd.CompletedNeurofibromatosis Type 2 | Vestibular SchwannomaChina
-
Betta Pharmaceuticals Co., Ltd.UnknownNon-small Cell Lung CancerChina
-
Sichuan Cancer Hospital and Research InstituteUnknown
-
Betta Pharmaceuticals Co., Ltd.Tigermed Consulting Co., LtdCompleted
-
Zhejiang Cancer HospitalUnknownNon-small Cell Lung Cancer | Brain MetastasesChina
-
Betta Pharmaceuticals Co., Ltd.Unknown
-
Cancer Institute and Hospital, Chinese Academy...UnknownNon-small Cell Lung CancerChina
-
Tianjin Medical University Cancer Institute and...RecruitingNon Small Cell Lung CancerChina